November 07, 2023
1 minutes watch
MADRID– In a video interview, Julia Rotow, MD, talked about favorable information from the ALINA research study in ALK– favorable non-small cell lung cancer provided at ESMO Congress.
The research study revealed that alectinib (Alecensa, Genentech) considerably enhanced DFS compared to chemotherapy in early-stage clients with resected ALK– favorable NSCLC.
” As we return home, I anticipate to see approvals in this area and truly ought to now be evaluating all of our early-stage clients not simply for EGFR, however likewise for ALK to get them optimum adjuvant treatment choices,” Rotow, scientific director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, informed Healio.
Referral:
- Solomon B, et al. Abstract LBA2. Provided at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.